View Older Stories View More Recent Stories
-
William Blair Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS)
-
Apellis Pharmaceuticals (APLS) to Receive up to $300M from Royalty Purchase Agreement with Sobi
-
Apellis Pharmaceuticals (APLS) and Sobi announce data from EMPALEVI study, showing efficacy
-
Apellis Pharmaceuticals (APLS) PT Raised to $29 at Wells Fargo
-
Biotech stocks Q1 earnings review
-
Apellis Pharmaceuticals (APLS) PT Lowered to $41 at Citi, Opens 90-Day Upside Catalyst Watch
-
Raymond James Downgrades Apellis Pharmaceuticals (APLS) to Outperform
-
Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 40c
-
Cantor Fitzgerald Starts Apellis Pharmaceuticals (APLS) at Overweight
-
Apellis Pharmaceuticals (APLS) Appoints Craig Wheeler to its Board
-
Apellis Pharmaceuticals (APLS) Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
-
Apellis Pharmaceuticals (APLS) PT Lowered to $75 at Raymond James
-
Apellis Pharmaceuticals (APLS) PT Lowered to $60 at Stifel
-
TD Cowen Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
-
Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 8c
-
Raymond James Reiterates Strong Buy Rating on Apellis Pharmaceuticals (APLS)
-
Piper Sandler on Apellis Pharmaceuticals (APLS): 'GA Doc Survey Suggests GA Market Growth In Doubt'
-
Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
-
Apellis Pharmaceuticals (APLS) Receives Approval of SYFOVRE in Australia for Geographic Atrophy
-
Apellis Pharmaceuticals (APLS) Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
-
Apellis Pharmaceuticals (APLS) Announces Keli Walbert to Join the Board of Directors
-
Apellis Pharmaceuticals (APLS) PT Raised to $26 at RBC Capital
-
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to Neutral
-
Morgan Stanley Starts Apellis Pharmaceuticals (APLS) at Equalweight
-
Piper Sandler Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
-
Apellis Pharmaceuticals (APLS) PT Lowered to $55 at Baird
-
Apellis Pharmaceuticals (APLS) PT Lowered to $30 at Scotiabank
-
Apellis Pharmaceuticals (APLS) PT Lowered to $32 at Piper Sandler
-
Apellis Pharmaceuticals (APLS) PT Lowered to $40 at Oppenheimer
-
Apellis Pharmaceuticals (APLS) PT Lowered to $57 at H.C. Wainwright
-
Apellis Pharmaceuticals (APLS) PT Lowered to $47 at BofA Securities
-
Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 17c
-
Citi Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
-
Apellis Pharmaceuticals (APLS) Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
-
Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
-
Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
-
Apellis Pharmaceuticals (APLS) PT Lowered to $92 at Baird
-
Apellis Pharmaceuticals (APLS) PT Lowered to $39 at Mizuho
-
Stifel Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
-
Apellis Pharmaceuticals (APLS) PT Lowered to $39 at Mizuho
-
Apellis Pharmaceuticals (APLS) Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy in the EU
-
Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
-
Apellis Pharmaceuticals (APLS) PT Lowered to $61 at BofA Securities
-
Apellis Pharmaceuticals (APLS) PT Raised to $42 at Mizuho
-
Apellis Pharmaceuticals (APLS) PT Raised to $96 at Baird
-
Apellis Pharmaceuticals (APLS) PT Raised to $82 at Jefferies
-
Apellis Pharmaceuticals (APLS) shares surge after study results
-
Apellis Pharmaceuticals (APLS) and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
-
Apellis Pharmaceuticals (APLS) Halted, News Pending
-
Apellis Pharmaceuticals (APLS) PT Lowered to $83 at H.C. Wainwright
